Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans

The duration, dynamics and determinants of SARS-CoV-2 antibody responses in individual healthcare workers

(2021) Sheila F Lumley et al.   CLINICAL INFECTIOUS DISEASES

Genetic Variants of SARS-CoV-2—What Do They Mean?

(2021) Adam S. Lauring et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evolution of antibody immunity to SARS-CoV-2

(2021) Christian Gaebler et al.   NATURE

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

(2021) Jennifer M. Dan et al.   SCIENCE

Persistent cellular immunity to SARS-CoV-2 infection

(2021) Gaëlle Breton et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2

(2021) Ludivine Grzelak et al.   JOURNAL OF INFECTIOUS DISEASES

Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies

(2021) Carlota Dobaño et al.   Translational Research

Rapid decline of neutralizing antibodies against SARS-CoV-2 among infected healthcare workers

(2021) Stéphane Marot et al.   Nature Communications

SARS-CoV-2 infection elicits a rapid neutralizing antibody response that correlates with disease severity

(2021) Benjamin Trinité et al.   Scientific Reports

SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies

(2021) Markus Hoffmann et al.   CELL

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

(2021) Victoria Jane Hall et al.   LANCET

Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies

(2021) Delphine Planas et al.   NATURE MEDICINE

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

(2021) David S. Khoury et al.   NATURE MEDICINE

Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351

(2021) Xiaoying Shen et al.   NEW ENGLAND JOURNAL OF MEDICINE

New SARS-CoV-2 Variants — Clinical, Public Health, and Vaccine Implications

(2021) Salim S. Abdool Karim et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

(2021) Nicole Doria-Rose et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody (IgA, IgG, and IgG Subtype) Responses to SARS-CoV-2 in Severe and Nonsevere COVID-19 Patients

(2021) Harshad P. Patil et al.   VIRAL IMMUNOLOGY

A Generic, Scalable, and Rapid Time-Resolved Förster Resonance Energy Transfer-Based Assay for Antigen Detection—SARS-CoV-2 as a Proof of Concept

(2021) Juuso Rusanen et al.   mBio

Seroprevalence and correlates of SARS-CoV-2 neutralizing antibodies from a population-based study in Bonn, Germany

(2021) N. Ahmad Aziz et al.   Nature Communications

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants

(2021) Gabriele Anichini et al.   Vaccines

Long-Term Persistence of Spike Protein Antibody and Predictive Modeling of Antibody Dynamics After Infection With Severe Acute Respiratory Syndrome Coronavirus 2

(2021) Louis Grandjean et al.   CLINICAL INFECTIOUS DISEASES

Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination

(2021) Emma C Wall et al.   LANCET

SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans

(2021) Jackson S. Turner et al.   NATURE

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

(2021) Delphine Planas et al.   NATURE

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

(2021) Jianying Liu et al.   NATURE

Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection

(2021) Zijun Wang et al.   NATURE

Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants

(2021) Venkata-Viswanadh Edara et al.   NEW ENGLAND JOURNAL OF MEDICINE

COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants

(2021) Pinja Jalkanen et al.   Nature Communications

SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees

(2021) Daryl Geers et al.   Science Immunology

Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020

(2020) Anu Haveri et al.   Eurosurveillance

Human neutralizing antibodies elicited by SARS-CoV-2 infection

(2020) Bin Ju et al.   NATURE

DNA vaccine protection against SARS-CoV-2 in rhesus macaques

(2020) Jingyou Yu et al.   SCIENCE

A human monoclonal antibody blocking SARS-CoV-2 infection

(2020) Chunyan Wang et al.   Nature Communications

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

(2020) Lisa A. Jackson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Seroprevalence of anti‐SARS‐CoV‐2 antibodies in COVID‐19 patients and healthy volunteers up to six months post disease onset

(2020) Patrícia Figueiredo‐Campos et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Neutralizing Antibodies Correlate with Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a High Attack Rate

(2020) Amin Addetia et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

(2020) Edward E. Walsh et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults

(2020) Evan J. Anderson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

(2020) Jeffrey Seow et al.   Nature Microbiology

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

(2020) Anita S. Iyer et al.   Science Immunology

Correlates of protection against SARS-CoV-2 in rhesus macaques

(2020) Katherine McMahan et al.   NATURE

IgA dominates the early neutralizing antibody response to SARS-CoV-2

(2020) Delphine Sterlin et al.   Science Translational Medicine